SEARCH

SEARCH BY CITATION

References

  • 1
    Stein PD, Matta F. Epidemiology and incidence: The scope of the problem and risk factors for development of venous thromboembolism. Clin Chest Med 2010;31:611628.
  • 2
    Goldhaber SZ, Dunn K, MacDougall RC. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest 2000;118:16801684.
  • 3
    Goldhaber SZ, Tapson VF and DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004;93:259262.
  • 4
    Anderson FA Jr, Zayaruzny M, Heit JA, et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007;82:777782.
  • 5
    Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007;167:14711475.
  • 6
    Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 2009;28:401409.
  • 7
    Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: Epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis 1996;26 (Suppl 2):4956.
  • 8
    Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614621.
  • 9
    Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ 2006;332:325329.
  • 10
    Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007;146:278288.
  • 11
    Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874879.
  • 12
    Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S453S.
  • 13
    Streiff MB, Lau BD. Thromboprophylaxis in non-surgical patients. Hematology Am Soc Hematol Educ Program 2012;2012:631637.
  • 14
    Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007;132:936945.
  • 15
    Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational cross-sectional study. Lancet 2008;371:387394.
  • 16
    Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: Are we detecting enough deep vein thrombosis? J R Soc Med 1989;82:203205.
  • 17
    Alikhan R, Peters F, Wilmott R, Cohen AT. Fatal pulmonary embolism in hospitalised patients: A necropsy review. J Clin Pathol 2004;57:12541257.
  • 18
    Michota FA. Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: The quality improvement process. J Gen Intern Med 2007;22:17621770.
  • 19
    US Department of Health and Human Services. The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. 2008. (Available at: at: http://www.surgeongeneral.gov/topics/deepvein/ on August 30, 2010).
  • 20
    Shekelle PG, Pronovost PJ, Wachter RM, et al. The top patient safety strategies that can be encouraged for adoption now. Ann Intern Med. 2013;158:365368.
  • 21
    Shekelle PG, Wachter RM, Pronovost PJ, et al. Making Health Care Safer II: An Updated Critical Analysis of the Evidence for Patient Safety Practices. Evidence Report No. 211. AHRQ 2013; Publication No. 13-E001-EF.
  • 22
    Durieux P, Nizard R, Ravaud P, et al. A clinical decision support system for prevention of venous thromboembolism: Effect on physician behavior. JAMA 2000;283:28162821.
  • 23
    Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005;352:969977.
  • 24
    Bauer JB, Chun DS, Karpinski TA. Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital. Am J Health Syst Pharm 2008;65:16431647.
  • 25
    Bullock-Palmer RP, Weiss S, Hyman C. Innovative approaches to increase deep vein thrombosis prophylaxis rate resulting in a decrease in hospital-acquired deep vein thrombosis at a tertiary-care teaching hospital. J Hosp Med 2008;3:148155.
  • 26
    Galanter WL, Thambi M, Rosencranz H, et al. Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. Am J Health Syst Pharm 2010;67:12651273.
  • 27
    Fiumara K, Piovella C, Hurwitz S, et al. Multi-screen electronic alerts to augment venous thromboembolism prophylaxis. Thromb Haemost 2010;103:312317.
  • 28
    Maynard GA, Morris TA, Jenkins IH, et al. Optimizing prevention of hospital-acquired venous thromboembolism (VTE): Prospective validation of a VTE risk assessment model. J Hosp Med 2010;5:1018.
  • 29
    Haut ER, Lau BD, Kraenzlin FS, et al. Improved prophylaxis and decreased preventable harm with a mandatory computerized clinical decision support tool for venous thromboembolism (VTE) prophylaxis in trauma. JAMA-Surg 2012;147:901907.
  • 30
    Streiff MB, Carolan H, Hobson DB, et al. Lessons learnt from the John Hopkins multi-disciplinary venous thromboembolism (venous thromboembolism) prevention collaborative. BMJ 2012;344:e3935.
  • 31
    Samama MM, Cohen AT, Darmon JY, et al. (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. NEJM 1999;341:793800.
  • 32
    Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107(Suppl 1):I9I16.
  • 33
    Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. JAMA 2011;305:24622463.
  • 34
    Prandoni P, Lensing AW, Bernardi E, et al. The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis. Thromb Haemost 2002;88:402406.
  • 35
    Linkins LA, Pasquale P, Paterson S, Kearon C. Change in thrombus length on venous ultrasound and recurrent deep vein thrombosis. Arch Intern Med 2004;164:17931796.
  • 36
    Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692694.
  • 37
    Peterson GM, Drake CI, Jupe DM, et al. Educational campaign to improve the prevention of postoperative venous thromboembolism. J Clin Pharm Ther 1999;24:279287.
  • 38
    Tooher R, Middleton P, Pham C, et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg 2005;241:397415.
  • 39
    Aboagye JK, Lau BD, Schneider EB, Streiff MB, Haut ER. Linking processes and outcomes: A key strategy to prevent and report harm from venous thromboembolism in surgical patients. JAMA Surg 2013;148:299300.
  • 40
    Fanikos J, Stevens LA, Labreche M, et al. Adherence to pharmacological thromboprophylaxis orders in hospitalized patients. Am J Med 2010;123:536541.
  • 41
    Shermock KM, Lau BD, Streiff MB, et al. Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: Implications for novel intervention strategies. Abstract; 2013. International Society for Pharmacoeconomics and Outcomes Research.
  • 42
    Haut ER, Lau BD, Streiff MB. New oral anticoagulants for venous thromboembolism (VTE) prophylaxis: Are we at the point of diminishing returns? BMJ 2012;344:e3820.
  • 43
    Streiff MB, Haut ER. The CMS ruling on venous thromboembolism after total knee or hip arthroplasty: Weighing risks and benefits. JAMA 2009;301:10631065.